{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:55:59Z","timestamp":1790798159638,"version":"4.1.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Capital Health Research and Development of Special","award":["2026-2-1031"],"award-info":[{"award-number":["2026-2-1031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"DOI":"10.1186\/s10020-026-01623-0","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:28:04Z","timestamp":1788409684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research advances on CD47 in digestive system cancers: from molecular mechanisms to clinical translation"],"prefix":"10.1186","volume":"32","author":[{"given":"Haolin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6917-7234","authenticated-orcid":false,"given":"Bangwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"1623_CR1","doi-asserted-by":"publisher","unstructured":"Ahn JS, Hong JY, Park JO, et al. Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors. Cancer Res Treat. 2025. https:\/\/doi.org\/10.4143\/crt.2025.820.","DOI":"10.4143\/crt.2025.820"},{"issue":"1","key":"1623_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1186\/s12876-025-04371-3","volume":"25","author":"OH Aktepe","year":"2025","unstructured":"Aktepe OH, Kurtulan O, Dama PE, et al. Prognostic importance of CD47 expression on survival of colorectal cancer. BMC Gastroenterol. 2025;25(1):757.","journal-title":"BMC Gastroenterol"},{"key":"1623_CR3","doi-asserted-by":"publisher","first-page":"106264","DOI":"10.1016\/j.phrs.2022.106264","volume":"181","author":"A Alausa","year":"2022","unstructured":"Alausa A, Lawal KA, Babatunde OA, et al. Overcoming immunotherapeutic resistance in PDAC: SIRP\u03b1-CD47 blockade. Pharmacol Res. 2022;181:106264.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1623_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4174\/astr.2025.108.2.98","volume":"108","author":"ED Amare","year":"2025","unstructured":"Amare ED, Lee S, Choi D, et al. Exploring the prognostic role of cluster of differentiation 47 in patients with advanced pancreatic cancer: a comparative cohort study. Ann Surg Treat Res. 2025;108(2):98\u2013106.","journal-title":"Ann Surg Treat Res"},{"issue":"1","key":"1623_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","volume":"19","author":"AA Barkal","year":"2018","unstructured":"Barkal AA, Weiskopf K, Kao KS, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19(1):76\u201384.","journal-title":"Nat Immunol"},{"issue":"7769","key":"1623_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392\u20136.","journal-title":"Nature"},{"issue":"14","key":"1623_CR7","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.3390\/cancers14143366","volume":"14","author":"LM Behrens","year":"2022","unstructured":"Behrens LM, van den Berg TK, van Egmond M. Targeting the CD47-SIRP\u03b1 Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils. Cancers (Basel). 2022;14(14):3366.","journal-title":"Cancers (Basel)"},{"issue":"Suppl 3","key":"1623_CR8","first-page":"A233","volume":"8","author":"J Berlin","year":"2020","unstructured":"Berlin J, Harb W, Adjei A, et al. 385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed\/refractory malignancy: initial monotherapy results. J Immunother Cancer. 2020;8(Suppl 3):A233.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1623_CR9","doi-asserted-by":"publisher","first-page":"8550","DOI":"10.4049\/jimmunol.177.12.8550","volume":"177","author":"D Braun","year":"2006","unstructured":"Braun D, Galibert L, Nakajima T, et al. Semimature stage: a checkpoint in a dendritic cell maturation program that allows for functional reversion after signal-regulatory protein-alpha ligation and maturation signals. J Immunol. 2006;177(12):8550\u20139.","journal-title":"J Immunol"},{"issue":"41","key":"1623_CR10","doi-asserted-by":"publisher","first-page":"42393","DOI":"10.1074\/jbc.M407631200","volume":"279","author":"JE Brittain","year":"2004","unstructured":"Brittain JE, Han J, Ataga KI, et al. Mechanism of CD47-induced alpha4beta1 integrin activation and adhesion in sickle reticulocytes. J Biol Chem. 2004;279(41):42393\u2013402.","journal-title":"J Biol Chem"},{"issue":"12","key":"1623_CR11","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1172\/JCI13315","volume":"107","author":"E Brown","year":"2001","unstructured":"Brown E. Integrin-associated protein (CD47): an unusual activator of G protein signaling. J Clin Invest. 2001;107(12):1499\u2013500.","journal-title":"J Clin Invest"},{"issue":"3","key":"1623_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","volume":"11","author":"EJ Brown","year":"2001","unstructured":"Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001;11(3):130\u20135.","journal-title":"Trends Cell Biol"},{"issue":"6 Pt 1","key":"1623_CR13","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1083\/jcb.111.6.2785","volume":"111","author":"E Brown","year":"1990","unstructured":"Brown E, Hooper L, Ho T, et al. Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins. J Cell Biol. 1990;111(6 Pt 1):2785\u201394.","journal-title":"J Cell Biol"},{"issue":"15_suppl","key":"1623_CR14","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1200\/JCO.2021.39.15_suppl.2623","volume":"39","author":"S Champiat","year":"2021","unstructured":"Champiat S, Cassier PA, Kotecki N, et al. Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRP\u03b1 inhibitor: results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors. J Clin Oncol. 2021;39(15_suppl):2623.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1623_CR15","doi-asserted-by":"publisher","first-page":"e003737","DOI":"10.1136\/jitc-2021-003737","volume":"10","author":"H Chen","year":"2022","unstructured":"Chen H, Yang Y, Deng Y, et al. Delivery of CD47 blocker SIRP\u03b1-Fc by CAR-T cells enhances antitumor efficacy. J Immunother Cancer. 2022;10(2):e003737.","journal-title":"J Immunother Cancer"},{"key":"1623_CR16","doi-asserted-by":"publisher","first-page":"1511423","DOI":"10.3389\/fphar.2024.1511423","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Mao K, Han D, et al. Nanomedicine based on chemotherapy-induced immunogenic death combined with immunotherapy to enhance antitumor immunity. Front Pharmacol. 2024;15:1511423.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1623_CR17","doi-asserted-by":"publisher","first-page":"111478","DOI":"10.1016\/j.isci.2024.111478","volume":"27","author":"C Chen","year":"2024","unstructured":"Chen C, Lu F, Huang H, et al. Translating CD47-targeted therapy in gastrointestinal cancers: Insights from preclinical to clinical studies. iScience. 2024;27(12):111478.","journal-title":"iScience"},{"key":"1623_CR18","doi-asserted-by":"publisher","first-page":"217934","DOI":"10.1016\/j.canlet.2025.217934","volume":"632","author":"Z Chen","year":"2025","unstructured":"Chen Z, Cai Y, Zhao K, et al. A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment. Cancer Lett. 2025;632:217934.","journal-title":"Cancer Lett"},{"key":"1623_CR19","doi-asserted-by":"publisher","first-page":"150066","DOI":"10.1016\/j.bbrc.2024.150066","volume":"720","author":"CH Chuang","year":"2024","unstructured":"Chuang CH, Zhen YY, Ma JY, et al. CD47-mediated immune evasion in early-stage lung cancer progression. Biochem Biophys Res Commun. 2024;720:150066.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1623_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1182\/blood.V94.2.642","volume":"94","author":"J Chung","year":"1999","unstructured":"Chung J, Wang XQ, Lindberg FP, et al. Thrombospondin-1 acts via IAP\/CD47 to synergize with collagen in alpha2beta1-mediated platelet activation. Blood. 1999;94(2):642\u20138.","journal-title":"Blood"},{"key":"1623_CR21","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT05330429, Study of Magrolimab Given Together With FOLFIRI\/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC). 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05330429. Cited 2026 Sep 2."},{"key":"1623_CR22","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT05002127, A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06). 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05002127. Cited 2026 Aug 10."},{"key":"1623_CR23","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT05167409, A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer. 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05167409. Cited 2026 Apr 5."},{"key":"1623_CR24","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT05482893, A Study of PT886 in Adults With Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas (TWINPEAK). 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05482893. Cited 2026 Apr 5."},{"key":"1623_CR25","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT05805956, IMM2902 in Patients With Advanced Solid Tumors Expressing HER2. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05805956. Cited 2026 Apr 5."},{"key":"1623_CR26","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT05960955, Study of AK117 in Neoadjuvant Therapy for Gastric\/Gastroesophageal Junction Cancer. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05960955. Cited 2026 Mar 8."},{"issue":"1","key":"1623_CR27","doi-asserted-by":"publisher","first-page":"e70245","DOI":"10.1002\/cncr.70245","volume":"132","author":"P Danpanichkul","year":"2026","unstructured":"Danpanichkul P, Pang Y, Tothanarungroj P, et al. Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries. Cancer. 2026;132(1):e70245.","journal-title":"Cancer"},{"issue":"5","key":"1623_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2024027506","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Vyas P, Huls G, et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025;146(5):601\u201311.","journal-title":"Blood"},{"issue":"11","key":"1623_CR29","doi-asserted-by":"publisher","first-page":"e012463","DOI":"10.1136\/jitc-2025-012463","volume":"13","author":"F Du","year":"2025","unstructured":"Du F, Jiang M, Qiu J, Wang Z, Ning P. Engineering TME-activated CD47-specific CAR macrophage via Arg1 promoter for safe and effective solid tumor immunotherapy. J Immunother Cancer. 2025;13(11):e012463.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1623_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/egjp.egjp_19_24","volume":"44","author":"AS El Dein Mohamed","year":"2024","unstructured":"El Dein Mohamed AS, El Hosary EM, Gadallah MSA. CD47 plays dual role in colorectal carcinoma, independently on CD 68: an immunohistochemical study. Egypt J Pathol. 2024;44(2):91\u2013101.","journal-title":"Egypt J Pathol"},{"issue":"3","key":"1623_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11523-025-01130-y","volume":"20","author":"C Eng","year":"2025","unstructured":"Eng C, Lakhani NJ, Philip PA, et al. A phase 1b\/2 study of the anti-CD47 antibody magrolimab with cetuximab in patients with colorectal cancer and other solid tumors. Target Oncol. 2025;20(3):519\u201330.","journal-title":"Target Oncol"},{"key":"1623_CR32","unstructured":"EU Clinical Trials Register. A phase I study of the mesothelin x CD47 antibody NI-1801, as a single agent and in combination with anti-PD-1 antibody, or with paclitaxel in solid cancers. n.d. EUCT number: 2024\u2013517752\u201335\u201300. Updated June 17, 2026. Available from: https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2024-517752-35-00. Cited 2026 Jun 22."},{"issue":"22","key":"1623_CR33","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1158\/0008-5472.CAN-23-0783","volume":"83","author":"Y Fan","year":"2023","unstructured":"Fan Y, Song S, Li Y, et al. Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases. Cancer Res. 2023;83(22):3726\u201338.","journal-title":"Cancer Res"},{"issue":"1","key":"1623_CR34","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1038\/s41467-021-25475-w","volume":"12","author":"G Fenalti","year":"2021","unstructured":"Fenalti G, Villanueva N, Griffith M, et al. Structure of the human marker of self 5-transmembrane receptor CD47. Nat Commun. 2021;12(1):5218.","journal-title":"Nat Commun"},{"issue":"4","key":"1623_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000496027","volume":"86","author":"R Fujiwara-Tani","year":"2019","unstructured":"Fujiwara-Tani R, Sasaki T, Ohmori H, et al. Concurrent Expression of CD47 and CD44 in Colorectal Cancer Promotes Malignancy. Pathobiology. 2019;86(4):182\u20139.","journal-title":"Pathobiology"},{"issue":"20","key":"1623_CR36","doi-asserted-by":"publisher","first-page":"e2308310","DOI":"10.1002\/advs.202308310","volume":"11","author":"K Gong","year":"2024","unstructured":"Gong K, Jiao J, Wu Z, et al. Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer. Adv Sci (Weinh). 2024;11(20):e2308310.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"1623_CR37","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.32604\/or.2025.071708","volume":"33","author":"X Guo","year":"2025","unstructured":"Guo X, Fu Y, Baran N, et al. CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge. Oncol Res. 2025;33(11):3375\u201385.","journal-title":"Oncol Res"},{"issue":"19","key":"1623_CR38","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-24-0176","volume":"84","author":"Y Hao","year":"2024","unstructured":"Hao Y, He H, et al. CD47-SIRP\u03b1 Blockade Sensitizes Head and Neck Squamous Cell Carcinoma to Cetuximab by Enhancing Macrophage Adhesion to Cancer Cells. Cancer Res. 2024;84(19):3189\u2013206.","journal-title":"Cancer Res"},{"issue":"1","key":"1623_CR39","doi-asserted-by":"publisher","first-page":"1824323","DOI":"10.1080\/2162402X.2020.1824323","volume":"9","author":"MAJM Hendriks","year":"2020","unstructured":"Hendriks MAJM, Ploeg EM, Koopmans I, et al. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRP\u03b1 \u201cdon\u2019t eat me\u201d immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. Oncoimmunology. 2020;9(1):1824323.","journal-title":"Oncoimmunology"},{"issue":"72","key":"1623_CR40","doi-asserted-by":"publisher","first-page":"eabl9330","DOI":"10.1126\/sciimmunol.abl9330","volume":"7","author":"RC Hsieh","year":"2022","unstructured":"Hsieh RC, Krishnan S, Wu RC, et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol. 2022;7(72):eabl9330.","journal-title":"Sci Immunol"},{"issue":"9","key":"1623_CR41","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.7150\/thno.40860","volume":"10","author":"T Hu","year":"2020","unstructured":"Hu T, Liu H, Liang Z, et al. Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis. Theranostics. 2020;10(9):4056\u201372.","journal-title":"Theranostics"},{"issue":"3","key":"1623_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s43018-023-00691-z","volume":"5","author":"C Huang","year":"2024","unstructured":"Huang C, Wang X, Wang Y, et al. Sirp\u03b1 on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47. Nat Cancer. 2024;5(3):500\u201316.","journal-title":"Nat Cancer"},{"issue":"4","key":"1623_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/ATVBAHA.107.158154","volume":"28","author":"JS Isenberg","year":"2008","unstructured":"Isenberg JS, Roberts DD, Frazier WA. CD47: a new target in cardiovascular therapy. Arterioscler Thromb Vasc Biol. 2008;28(4):615\u201321.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1623_CR44","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.surg.2008.07.009","volume":"144","author":"JS Isenberg","year":"2008","unstructured":"Isenberg JS, Maxhimer JB, Powers P, et al. Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1\/CD47 signaling. Surgery. 2008;144(5):752\u201361.","journal-title":"Surgery"},{"issue":"3","key":"1623_CR45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nrc2561","volume":"9","author":"JS Isenberg","year":"2009","unstructured":"Isenberg JS, Martin-Manso G, Maxhimer JB, et al. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer. 2009;9(3):182\u201394.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1623_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271\u201385.","journal-title":"Cell"},{"issue":"Suppl 1","key":"1623_CR47","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.14701\/ahbps.2022S1.BP-PP-1-3","volume":"26","author":"YK Jung","year":"2022","unstructured":"Jung YK, Kim H. CD47 expression in human gallbladder cancer and its clinicopathologic significance. Ann Hepatobiliary Pancreat Surg. 2022;26(Suppl 1):S230.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"50","key":"1623_CR48","doi-asserted-by":"publisher","first-page":"38923","DOI":"10.1074\/jbc.M110.172304","volume":"285","author":"S Kaur","year":"2010","unstructured":"Kaur S, Martin-Manso G, Pendrak ML, et al. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem. 2010;285(50):38923\u201332.","journal-title":"J Biol Chem"},{"issue":"2","key":"1623_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/jclinpath-2020-206611","volume":"74","author":"H Kim","year":"2021","unstructured":"Kim H, Bang S, Jee S, Paik SS, Jang K. Clinicopathological significance of CD47 expression in hepatocellular carcinoma. J Clin Pathol. 2021;74(2):111\u20135.","journal-title":"J Clin Pathol"},{"issue":"4","key":"1623_CR50","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/biomedicines11041117","volume":"11","author":"T Kobori","year":"2023","unstructured":"Kobori T, Ito Y, Sawada Y, et al. Cellular Membrane Localization of Innate Immune Checkpoint Molecule CD47 Is Regulated by Radixin in Human Pancreatic Ductal Adenocarcinoma Cells. Biomedicines. 2023;11(4):1117 Published 2023 Apr 7.","journal-title":"Biomedicines."},{"issue":"1","key":"1623_CR51","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13045-020-00989-w","volume":"13","author":"TC Kuo","year":"2020","unstructured":"Kuo TC, Chen A, Harrabi O, et al. Targeting the myeloid checkpoint receptor SIRP\u03b1 potentiates innate and adaptive immune responses to promote anti-tumor activity. J Hematol Oncol. 2020;13(1):160.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1623_CR52","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","volume":"22","author":"NJ Lakhani","year":"2021","unstructured":"Lakhani NJ, Chow LQM, Gainor JF, et al. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021;22(12):1740\u201351.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1623_CR53","doi-asserted-by":"publisher","first-page":"a006627","DOI":"10.1101\/cshperspect.a006627","volume":"2","author":"PR Lawler","year":"2012","unstructured":"Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med. 2012;2(5):a006627.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"1623_CR54","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1158\/2767-9764.CRC-25-0332","volume":"5","author":"RW Lentz","year":"2025","unstructured":"Lentz RW, Lang J, Pitts TM, et al. Phase II clinical trial and preclinical evaluation of a novel CD47 blockade combination in refractory microsatellite-stable metastatic colorectal cancer. Cancer Res Commun. 2025;5(11):2039\u201352.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"1623_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10388-025-01152-5","volume":"23","author":"J Li","year":"2026","unstructured":"Li J, Ozawa Y, Mozumi T, et al. Expression of cluster of differentiation 47 (CD47) and signal regulatory protein alpha (SIRP\u03b1) as prognostic biomarkers and potentially therapeutic targets in esophageal squamous cell carcinoma. Esophagus. 2026;23(1):251\u201360.","journal-title":"Esophagus"},{"key":"1623_CR56","doi-asserted-by":"publisher","first-page":"153330","DOI":"10.1016\/j.bbrc.2026.153330","volume":"802","author":"Y Li","year":"2026","unstructured":"Li Y, He X, Zhou H, et al. Clinical advances in CD47-SIRP\u03b1 axis-targeted cancer immunotherapy: Mechanisms, strategies, challenges, and future perspectives. Biochem Biophys Res Commun. 2026;802:153330.","journal-title":"Biochem Biophys Res Commun"},{"key":"1623_CR57","doi-asserted-by":"publisher","first-page":"887463","DOI":"10.3389\/fbioe.2022.887463","volume":"10","author":"H Liao","year":"2022","unstructured":"Liao H, Niu C. Role of CD47-SIRP\u03b1 Checkpoint in Nanomedicine-Based Anti-Cancer Treatment. Front Bioeng Biotechnol. 2022;10:887463.","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"1623_CR58","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jmb.2006.09.079","volume":"365","author":"Y Liu","year":"2007","unstructured":"Liu Y, Tong Q, Zhou Y, et al. Functional elements on SIRPalpha IgV domain mediate cell surface binding to CD47. J Mol Biol. 2007;365(3):680\u201393.","journal-title":"J Mol Biol"},{"issue":"10","key":"1623_CR59","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209\u201315.","journal-title":"Nat Med"},{"issue":"3","key":"1623_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7150\/jca.80725","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu Z, Chen H, Ta N, et al. Anti-CD47 Antibody Enhances the Efficacy of Chemotherapy in Patients with Gastric Cancer Liver Metastasis. J Cancer. 2023;14(3):350\u20139.","journal-title":"J Cancer"},{"issue":"1","key":"1623_CR61","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang Y, Yang Y, et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):104.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1623_CR62","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s11658-025-00805-8","volume":"30","author":"J Liu","year":"2025","unstructured":"Liu J, Ma J, Zhang Y, et al. DGKs in lipid signaling and disease intervention: structural basis, pathological mechanisms, and emerging therapeutic strategies. Cell Mol Biol Lett. 2025;30(1):129.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"1623_CR63","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13046-024-03145-1","volume":"43","author":"Q Luo","year":"2024","unstructured":"Luo Q, Shen F, Zhao S, et al. LINC00460\/miR-186-3p\/MYC feedback loop facilitates colorectal cancer immune escape by enhancing CD47 and PD-L1 expressions. J Exp Clin Cancer Res. 2024;43(1):225.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1623_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12951-020-0571-2","volume":"18","author":"L Ma","year":"2020","unstructured":"Ma L, Zhu M, Gai J, et al. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. J Nanobiotechnology. 2020;18(1):12.","journal-title":"J Nanobiotechnology"},{"issue":"2","key":"1623_CR65","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tcb.2008.12.001","volume":"19","author":"T Matozaki","year":"2009","unstructured":"Matozaki T, Murata Y, Okazawa H, et al. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol. 2009;19(2):72\u201380.","journal-title":"Trends Cell Biol"},{"issue":"33","key":"1623_CR66","doi-asserted-by":"publisher","first-page":"10001","DOI":"10.1021\/bi0341408","volume":"42","author":"JF McDonald","year":"2003","unstructured":"McDonald JF, Dimitry JM, Frazier WA. An amyloid-like C-terminal domain of thrombospondin-1 displays CD47 agonist activity requiring both VVM motifs. Biochemistry. 2003;42(33):10001\u201311.","journal-title":"Biochemistry"},{"issue":"9","key":"1623_CR67","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00262-023-03465-9","volume":"72","author":"E Montero","year":"2023","unstructured":"Montero E, Isenberg JS. The TSP1-CD47-SIRP\u03b1 interactome: an immune triangle for the checkpoint era. Cancer Immunol Immunother. 2023;72(9):2879\u201388.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"1623_CR68","doi-asserted-by":"publisher","first-page":"e013283","DOI":"10.1136\/jitc-2025-013283","volume":"13","author":"L Nan","year":"2025","unstructured":"Nan L, Chen L, Huang W, et al. Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance. J Immunother Cancer. 2025;13(12):e013283.","journal-title":"J Immunother Cancer"},{"issue":"5473","key":"1623_CR69","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg PA, Zheleznyak A, Fang YF, et al. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051\u20134.","journal-title":"Science"},{"issue":"9","key":"1623_CR70","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1182\/blood-2004-08-2980","volume":"105","author":"M Olsson","year":"2005","unstructured":"Olsson M, Bruhns P, Frazier WA, et al. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood. 2005;105(9):3577\u201382.","journal-title":"Blood"},{"issue":"4","key":"1623_CR71","doi-asserted-by":"publisher","first-page":"e100242","DOI":"10.1136\/egastro-2025-100242","volume":"3","author":"J Otuagomah","year":"2025","unstructured":"Otuagomah J, Newcomb A, Gwag T, Wang S. CD47: an immunoregulatory nexus in liver and gastrointestinal disorders. eGastroenterology. 2025;3(4):e100242.","journal-title":"eGastroenterology"},{"issue":"1","key":"1623_CR72","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13045-019-0822-6","volume":"12","author":"Y Pan","year":"2019","unstructured":"Pan Y, Lu F, Fei Q, et al. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. J Hematol Oncol. 2019;12(1):124.","journal-title":"J Hematol Oncol"},{"key":"1623_CR73","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.tranon.2024.102240","volume":"52","author":"Y Pan","year":"2025","unstructured":"Pan Y, Yin Q, Wang Z, et al. AFP shields hepatocellular carcinoma from macrophage phagocytosis by regulating HuR-mediated CD47 translocation in cellular membrane. Transl Oncol. 2025;52:102240.","journal-title":"Transl Oncol"},{"issue":"Suppl 2","key":"1623_CR74","first-page":"A582","volume":"12","author":"X Pang","year":"2024","unstructured":"Pang X, Zhong T, Jin C, et al. AK132, a first-in-class asymmetric Claudin18.2\/CD47 bispecific antibody for cancer immunotherapy. J Immunother Cancer. 2024;12(Suppl 2):A582.","journal-title":"J Immunother Cancer."},{"key":"1623_CR75","doi-asserted-by":"publisher","first-page":"1686180","DOI":"10.3389\/fonc.2025.1686180","volume":"15","author":"M Pei","year":"2025","unstructured":"Pei M, Dai XD, Jiang XF, et al. A CD47 antibody with minimized erythrocyte and thrombocyte toxicities. Front Oncol. 2025;15:1686180.","journal-title":"Front Oncol"},{"issue":"3","key":"1623_CR76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/antib14030058","volume":"14","author":"S Peshin","year":"2025","unstructured":"Peshin S, Bashir F, Kodali NA, et al. Immunotherapy in GI cancers: lessons from key trials and future clinical applications. Antibodies. 2025;14(3):58.","journal-title":"Antibodies"},{"issue":"4","key":"1623_CR77","doi-asserted-by":"publisher","first-page":"103024","DOI":"10.1016\/j.jbc.2023.103024","volume":"299","author":"NP Podolnikova","year":"2023","unstructured":"Podolnikova NP, Key S, Wang X, et al. The CIS association of CD47 with integrin Mac-1 regulates macrophage responses by stabilizing the extended integrin conformation. J Biol Chem. 2023;299(4):103024.","journal-title":"J Biol Chem"},{"issue":"10","key":"1623_CR78","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/s41418-024-01347-w","volume":"31","author":"R Polara","year":"2024","unstructured":"Polara R, Ganesan R, Pitson SM, Robinson N. Cell autonomous functions of CD47 in regulating cellular plasticity and metabolic plasticity. Cell Death Differ. 2024;31(10):1255\u201366.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1623_CR79","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","volume":"10","author":"T Qu","year":"2022","unstructured":"Qu T, Li B, Wang Y. Targeting CD47\/SIRP\u03b1 as a therapeutic strategy, where we are and where we are headed. Biomark Res. 2022;10(1):20.","journal-title":"Biomark Res"},{"issue":"6","key":"1623_CR80","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.1097\/MPA.0000000000002489","volume":"54","author":"L Rahib","year":"2025","unstructured":"Rahib L, Coffin T, Kenner B. Factors driving pancreatic cancer survival rates. Pancreas. 2025;54(6):e530\u20136.","journal-title":"Pancreas"},{"issue":"10","key":"1623_CR81","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.bbamcr.2006.08.001","volume":"1763","author":"GM Rath","year":"2006","unstructured":"Rath GM, Schneider C, Dedieu S, et al. The C-terminal CD47\/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochim Biophys Acta. 2006;1763(10):1125\u201334.","journal-title":"Biochim Biophys Acta"},{"issue":"48","key":"1623_CR82","doi-asserted-by":"publisher","first-page":"e2509875122","DOI":"10.1073\/pnas.2509875122","volume":"122","author":"S Rauf","year":"2025","unstructured":"Rauf S, Smirnova A, Chang A, Liu Y, Jiang Y. Immunogenic cell death unlocks the potential for combined radiation and immunotherapy. Proc Natl Acad Sci U S A. 2025;122(48):e2509875122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16_suppl","key":"1623_CR83","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1200\/JCO.2026.44.16_suppl.4192","volume":"44","author":"A Saeed","year":"2026","unstructured":"Saeed A, Xu RH, Singh H, et al. Spevatamig (PT886), a claudin 18.2 (CLDN18.2)\/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2026;44(16_suppl):4192.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1623_CR84","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Al Malki MM, Asch AS, et al. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023;41(15):2815\u201326.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1623_CR85","doi-asserted-by":"publisher","first-page":"TPS8128","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8128","volume":"43","author":"J Sands","year":"2025","unstructured":"Sands J, Henry JT, Spira AI, et al. An open-label, multicenter, phase 1\/2 study of peluntamig (PT217), an anti-DLL3\/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study). J Clin Oncol. 2025;43(16_suppl):TPS8128.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1623_CR86","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4049\/jimmunol.1100528","volume":"187","author":"M Sato-Hashimoto","year":"2011","unstructured":"Sato-Hashimoto M, Saito Y, Ohnishi H, et al. Signal regulatory protein \u03b1 regulates the homeostasis of T lymphocytes in the spleen. J Immunol. 2011;187(1):291\u20137.","journal-title":"J Immunol"},{"issue":"1","key":"1623_CR87","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s11658-025-00786-8","volume":"30","author":"KE Shalaby","year":"2025","unstructured":"Shalaby KE, Abdelalim EM. Hypoimmune stem cells and islets: hype or a true breakthrough in diabetes treatment? Cell Mol Biol Lett. 2025;30(1):112.","journal-title":"Cell Mol Biol Lett"},{"issue":"7","key":"1623_CR88","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00262-020-02806-2","volume":"70","author":"M Shi","year":"2021","unstructured":"Shi M, Gu Y, Jin K, et al. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunol Immunother. 2021;70(7):1831\u201340.","journal-title":"Cancer Immunol Immunother"},{"issue":"672","key":"1623_CR89","doi-asserted-by":"publisher","first-page":"eabp8309","DOI":"10.1126\/scitranslmed.abp8309","volume":"14","author":"H Shi","year":"2022","unstructured":"Shi H, Wang X, Li F, et al. CD47-SIRP\u03b1 axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis. Sci Transl Med. 2022;14(672):eabp8309.","journal-title":"Sci Transl Med."},{"issue":"4_suppl","key":"1623_CR90","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/JCO.2025.43.4_suppl.332","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara K, Wainberg ZA, Tabernero J, et al. Final analysis of the randomized phase 2 part of the ASPEN-06 study: a phase 2\/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric\/gastroesophageal cancer. J Clin Oncol. 2025;43(4_suppl):332.","journal-title":"J Clin Oncol."},{"issue":"12","key":"1623_CR91","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol. 2019;37(12):946\u201353.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1623_CR92","first-page":"3301","volume":"20","author":"X Song","year":"2020","unstructured":"Song X, Lu Z, Xu J. Targeting cluster of differentiation 47 improves the efficacy of anti-cytotoxic T-lymphocyte associated protein 4 treatment via antigen presentation enhancement in pancreatic ductal adenocarcinoma. Exp Ther Med. 2020;20(4):3301\u20139.","journal-title":"Exp Ther Med"},{"issue":"2","key":"1623_CR93","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3892\/or.2012.1831","volume":"28","author":"S Suzuki","year":"2012","unstructured":"Suzuki S, Yokobori T, Tanaka N, et al. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep. 2012;28(2):465\u201372.","journal-title":"Oncol Rep"},{"issue":"5","key":"1623_CR94","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1083\/jcb.200708043","volume":"180","author":"RK Tsai","year":"2008","unstructured":"Tsai RK, Discher DE. Inhibition of \u201cself\u201d engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008;180(5):989\u20131003.","journal-title":"J Cell Biol"},{"issue":"24","key":"1623_CR95","doi-asserted-by":"publisher","first-page":"e131882","DOI":"10.1172\/jci.insight.131882","volume":"4","author":"LC Tsao","year":"2019","unstructured":"Tsao LC, Crosby EJ, Trotter TN, et al. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight. 2019;4(24):e131882.","journal-title":"JCI Insight"},{"issue":"29","key":"1623_CR96","doi-asserted-by":"publisher","first-page":"e2026849118","DOI":"10.1073\/pnas.2026849118","volume":"118","author":"R Upton","year":"2021","unstructured":"Upton R, Banuelos A, Feng D, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021;118(29):e2026849118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1623_CR97","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tranon.2018.10.007","volume":"12","author":"K Vaeteewoottacharn","year":"2019","unstructured":"Vaeteewoottacharn K, Kariya R, Pothipan P, et al. Attenuation of CD47-SIRP\u03b1 signal in cholangiocarcinoma potentiates tumor-associated macrophage-mediated phagocytosis and suppresses intrahepatic metastasis. Transl Oncol. 2019;12(2):217\u201325.","journal-title":"Transl Oncol"},{"issue":"1","key":"1623_CR98","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s40425-019-0772-0","volume":"7","author":"E Voets","year":"2019","unstructured":"Voets E, Parad\u00e9 M, Lutje Hulsik D, et al. Functional characterization of the selective pan-allele anti-SIRP\u03b1 antibody ADU-1805 that blocks the SIRP\u03b1-CD47 innate immune checkpoint. J Immunother Cancer. 2019;7(1):340.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"1623_CR99","first-page":"A563","volume":"13","author":"ZA Wainberg","year":"2025","unstructured":"Wainberg ZA, et al. CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric\/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial. J Immunother Cancer. 2025;13(Suppl 2):A563.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1623_CR100","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1091\/mbc.9.4.865","volume":"9","author":"XQ Wang","year":"1998","unstructured":"Wang XQ, Frazier WA. The thrombospondin receptor CD47 (IAP) modulates and associates with alpha2 beta1 integrin in vascular smooth muscle cells. Mol Biol Cell. 1998;9(4):865\u201374.","journal-title":"Mol Biol Cell"},{"issue":"2","key":"1623_CR101","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1083\/jcb.147.2.389","volume":"147","author":"XQ Wang","year":"1999","unstructured":"Wang XQ, Lindberg FP, Frazier WA. Integrin-associated protein stimulates alpha2beta1-dependent chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases. J Cell Biol. 1999;147(2):389\u2013400.","journal-title":"J Cell Biol"},{"issue":"2","key":"1623_CR102","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","volume":"70","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ni H, Zhou S, et al. Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunol Immunother. 2021;70(2):365\u201376.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1623_CR103","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-025-01742-x","volume":"18","author":"JT Wang","year":"2025","unstructured":"Wang JT, Tseng CL, Teng HF, et al. HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRP\u03b1 pathway with high safety and preclinical efficacy for hematological and solid tumors. J Hematol Oncol. 2025;18(1):87.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1623_CR104","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1038\/s41590-025-02321-5","volume":"26","author":"CH Weng","year":"2025","unstructured":"Weng CH, Assouvie A, Dong L, et al. Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer. Nat Immunol. 2025;26(12):2296\u2013311.","journal-title":"Nat Immunol"},{"issue":"17","key":"1623_CR105","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1623_CR106","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3892\/ol.2024.14389","volume":"27","author":"F Wu","year":"2024","unstructured":"Wu F, Pang H, Li F, et al. Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review). Oncol Lett. 2024;27(6):256.","journal-title":"Oncol Lett"},{"issue":"7","key":"1623_CR107","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cac2.12579","volume":"44","author":"L Xiao","year":"2024","unstructured":"Xiao L, Zhang L, Guo C, et al. \u201cFind Me\u201d and \u201cEat Me\u201d signals: tools to drive phagocytic processes for modulating antitumor immunity. Cancer Commun (Lond). 2024;44(7):791\u2013832.","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"1623_CR108","doi-asserted-by":"publisher","first-page":"101162","DOI":"10.1016\/j.tranon.2021.101162","volume":"14","author":"ZH Ye","year":"2021","unstructured":"Ye ZH, Jiang XM, Huang MY, et al. Regulation of CD47 expression by interferon-gamma in cancer cells. Transl Oncol. 2021;14(9):101162.","journal-title":"Transl Oncol"},{"issue":"4","key":"1623_CR109","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.apsb.2022.12.016","volume":"13","author":"ZH Ye","year":"2023","unstructured":"Ye ZH, Yu WB, Huang MY, Chen J, Lu JJ. Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharm Sin b. 2023;13(4):1467\u201387.","journal-title":"Acta Pharm Sin b"},{"issue":"2_suppl","key":"1623_CR110","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1200\/JCO.2026.44.2_suppl.372","volume":"44","author":"LA Yu","year":"2026","unstructured":"Yu LA, Ning F, Zhou Z, et al. Dose-dependent antitumor activity of HCB101 plus ramucirumab and paclitaxel in previously treated gastric cancer. J Clin Oncol. 2026;44(2_suppl):372.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1623_CR111","doi-asserted-by":"publisher","first-page":"e01602","DOI":"10.1002\/advs.202501602","volume":"13","author":"PC Yu","year":"2026","unstructured":"Yu PC, Yue CX, Dong WZ, et al. Cancer Immunotherapy via Disruption of Integrin \u03b1v\u03b23 and CD47 Costabilization on Cancer Cell Surface. Adv Sci (Weinh). 2026;13(2):e01602.","journal-title":"Adv Sci (Weinh)"},{"key":"1623_CR112","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.drup.2024.101068","volume":"74","author":"B Zhang","year":"2024","unstructured":"Zhang B, Shi J, Shi X, et al. Development and evaluation of a human CD47\/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resist Updat. 2024;74:101068.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"1623_CR113","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1535-7163.MCT-25-0425","volume":"25","author":"H Zhang","year":"2026","unstructured":"Zhang H, He F, Cao L, et al. A novel anti-CD47 antibody TJH2201: efficacious tumor suppression with reduced RBC toxicity via a SIRP\u03b1-independent mechanism. Mol Cancer Ther. 2026;25(1):21\u201333.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1623_CR114","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1007\/s11033-023-08357-w","volume":"50","author":"W Zhao","year":"2023","unstructured":"Zhao W, Shen B, Cheng Q, et al. Roles of TSP1-CD47 signaling pathway in senescence of endothelial cells: cell cycle, inflammation and metabolism. Mol Biol Rep. 2023;50(5):4579\u201385.","journal-title":"Mol Biol Rep"},{"key":"1623_CR115","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s11658-026-00869-0","volume":"31","author":"W Zhao","year":"2026","unstructured":"Zhao W, Zheng H, Chang Y, et al. Astragaloside IV represses the immune evasion and acidic microenvironment of oral squamous cell carcinoma. Cell Mol Biol Lett. 2026;31:42.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"1623_CR116","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1038\/s41467-024-50136-z","volume":"15","author":"H Zhou","year":"2024","unstructured":"Zhou H, Wang W, Xu H, et al. Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRP\u03b1 blockade efficacy. Nat Commun. 2024;15(1):5759.","journal-title":"Nat Commun"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01623-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01623-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01623-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:02:29Z","timestamp":1790794949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01623-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01623-0","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"168"}}